Photo credit: www.investopedia.com

Sarepta Therapeutics Faces Setback After Patient Death

Overview of the Incident

Sarepta Therapeutics (SRPT) is under scrutiny following the death of a patient undergoing treatment with its gene therapy, Elevidys, for Duchenne muscular dystrophy. The pharmaceutical company announced that the patient succumbed to acute liver failure, a concerning development that has significantly impacted the company’s stock performance, causing shares to tumble over 20% in response to the news.

Details Surrounding the Patient’s Condition

The company clarified that acute liver injury is recognized as a potential side effect of Elevidys, along with other gene therapies. However, this incident marks the first reported death linked to the administration of this specific drug.

In its communications, Sarepta noted that the patient had previously experienced a cytomegalovirus (CMV) infection, which the healthcare provider suggested could have been a contributing factor to the liver failure.

Company’s Commitment to Safety

Sarepta is actively working with the Food and Drug Administration (FDA) to gather further details about the incident. They indicated their plans to revise the prescribing information, aiming to reflect this liver failure case and any necessary additional monitoring protocols.

Market Impact

The recent decline in Sarepta’s stock prices underscores the company’s precarious position. Over the past year, the company’s shares have depreciated by more than 35%, highlighting ongoing concerns regarding the safety and efficacy of its treatments.

UPDATE—This article has been edited to include a statement from Sarepta and the most recent share price information.

For additional information and continuing updates, stay tuned.

Source
www.investopedia.com